{"paper_id":"3a4d958e-e73f-4e18-843c-8be5a466c5b7","body_text":"Abstract\nMultiple myeloma remains a fatal, incurable disease. Most therapies are targeted to the cancer cell or T cell engagement. Little is known about the supporting myeloma microenvironment and its contribution to tumor fitness. Here, we expand upon the observation of human mast cells in the NSG-hIL6 myeloma patient derived xenograft mouse model to show mast cells decrease time to engraftment, promote increased myeloma engraftment and cause myeloma bone disease. We identify 10 mast cell secreted factors that together improve the survival of patient myeloma cells in vitro. Our results highlight the versatility of the NSG-hIL6 model to study microenvironmental interactions between human bone marrow cells and myeloma and confirm prior suggestions that clinical signs of disease, such as osteolytic lesions, may at least partially be related to non-malignant bone marrow microenvironmental cells, such as mast cells.\nCompeting Interest Statement\nALG -Consulting from Janssen, BMS/Celgene, Novartis, Abbvie, GSK, DSMB membership for Janssen. Research funding from Janssen, Novartis, CRISPR Therapeutics and Tmunity Therapeutics. DTV -Consulting for Takeda, Abbvie, Sanofi/Genzyme, Genentech/Roche, Karyopharm and CSL/Behring. Research funding from Takeda and Active Biotech.\nFootnotes\nConflicts: ALG -Consulting from Janssen, BMS/Celgene, Novartis, Abbvie, GSK, DSMB membership for Janssen. Research funding from Janssen, Novartis, CRISPR Therapeutics and Tmunity Therapeutics.\nDTV -Consulting for Takeda, Abbvie, Sanofi/Genzyme, Genentech/Roche, Karyopharm and CSL/Behring. Research funding from Takeda and Active Biotech.\nAll other authors have no relevant conflicts of interest to disclose.","source_license":"CC-BY-4.0","license_restricted":false}